Pear Therapeutics Announces Process Exploring Strategic Alternatives
Pear Therapeutics, Inc. - Class A (PEAR)
Company Research
Source: Business Wire
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value. The Company has engaged MTS Health Partners, L.P. to act as the Company’s exclusive financial advisor to assist in evaluating potential alternatives. MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry.As part of its process, Pear is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on at
Show less
Read more
Impact Snapshot
Event Time:
PEAR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEAR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEAR alerts
High impacting Pear Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
PEAR
News
- Pear Therapeutics, Inc. (NASDAQ: PEAR) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating.MarketBeat
- Pear Therapeutics, Inc. (NASDAQ: PEAR) was downgraded by analysts at Credit Suisse Group AG from an "outperform" rating to a "neutral" rating.MarketBeat
- Pear Therapeutics, Inc. (NASDAQ: PEAR) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare ConferenceBusiness Wire
- Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire
PEAR
Earnings
- 11/14/22 - Miss
PEAR
Sec Filings
- 3/17/23 - Form 8-K
- 2/24/23 - Form 8-K
- 2/17/23 - Form 4
- PEAR's page on the SEC website